Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : DGX-001,a first-in-class oral candidate targeting the gut-brain axis, is being developed for alzheimer's and parkinson's Disease. It modulates the vagus nerve through specific receptor interactions on enteroendocrine cells in the gut, resulting in a regu...
Product Name : DGX-001
Product Type : Peptide
Upfront Cash : Inapplicable
July 26, 2023
Reset All
